
    
      The primary objective of this study is to define the activity of Bendamustine for the
      treatment of T cells lymphomas. The activity of Bendamustine is determined by the response
      rate (RR) to the treatment within 22 days after intravenous infusion which enables to get a
      confidence interval of 95 % for the probability of an overall response rate (ORR).
    
  